Radiation plus chemo, then AK104 before rectal surgery
Treatments studied
Part of Cancer, Digestive system clinical trials.
This Phase 2 study tests whether giving radiation and chemotherapy along with a drug called AK104 before surgery can better treat stage II or III rectal cancer. The goal is to improve cancer control while keeping side effects acceptable before your tumor is removed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old, and can be any sex.
- You have stage II or III rectal cancer based on MRI or ultrasound pictures.
- Your rectal cancer has been confirmed by pathology (biopsy/surgery tissue).
- You have good overall blood counts and liver/kidney function on lab tests.
- You can have surgery for primary rectal cancer (not just comfort/palliative surgery).
- You have not had radiation before, and you agree to sign consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination for rectal cancer that hasn't spread far: a short course of radiation followed by two drugs (AK112 and CAPOX). The goal is to shrink the tumor before surgery and possibly avoid more aggressive treatments.
This trial combines a special type of radiation (MRI-guided adaptive radiotherapy) with an immunotherapy drug (PD-1 antibody) and chemotherapy (CAPOX) for locally advanced rectal cancer. The goal is to see if this combination can improve treatment outcomes.
This study tests a sequence of chemotherapy and radiation before and after surgery for rectal cancer. It compares giving more chemo between the end of radiation and surgery (consolidation) versus giving some chemo before radiation starts (induction). The goal is to see which order works better.
This trial studies giving long-course radiation and chemotherapy before surgery, plus an immunotherapy medicine (PD-1) to help the tumor shrink more. It’s for people with stage II or III rectal cancer that has not spread to distant organs.
This trial tests whether adding a new immunotherapy drug (cadonilimab) to standard chemoradiation before surgery helps patients with locally advanced rectal cancer. It aims to improve treatment outcomes by using a shorter course of radiation followed by a combination of the immunotherapy and chemotherapy.
This trial tests whether combining short-course radiation with an immune therapy drug (AK112) plus chemotherapy before surgery is better than radiation alone for locally advanced rectal cancer. It aims to shrink tumors and improve outcomes without needing stronger treatments later.
Hear when a new Locally Advanced Rectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.